PT  - JOURNAL ARTICLE
AU  - Tamura, Kenji
AU  - Kurihara, Hiroaki
AU  - Yonemori, Kan
AU  - Tsuda, Hitoshi
AU  - Suzuki, Junko
AU  - Kono, Yuzuru
AU  - Honda, Natsuki
AU  - Kodaira, Makoto
AU  - Yamamoto, Harukaze
AU  - Yunokawa, Mayu
AU  - Shimizu, Chikako
AU  - Hasegawa, Koki
AU  - Kanayama, Yousuke
AU  - Nozaki, Satoshi
AU  - Kinoshita, Takayuki
AU  - Wada, Yasuhiro
AU  - Tazawa, Shusaku
AU  - Takahashi, Kazuhiro
AU  - Watanabe, Yasuyoshi
AU  - Fujiwara, Yasuhiro
TI  - <sup>64</sup>Cu-DOTA-Trastuzumab PET Imaging in Patients with HER2-Positive Breast Cancer
AID  - 10.2967/jnumed.112.118612
DP  - 2013 Nov 01
TA  - Journal of Nuclear Medicine
PG  - 1869--1875
VI  - 54
IP  - 11
4099  - http://jnm.snmjournals.org/content/54/11/1869.short
4100  - http://jnm.snmjournals.org/content/54/11/1869.full
SO  - J Nucl Med2013 Nov 01; 54
AB  - The purpose of this study was to determine the safety, distribution, internal dosimetry, and initial human epidermal growth factor receptor 2 (HER2)–positive tumor images of 64Cu-DOTA-trastuzumab in humans. Methods: PET was performed on 6 patients with primary or metastatic HER2-positive breast cancer at 1, 24, and 48 h after injection of approximately 130 MBq of the probe 64Cu-DOTA-trastuzumab. Radioactivity data were collected from the blood, urine, and normal-tissue samples of these 6 patients, and the multiorgan biodistribution and internal dosimetry of the probe were evaluated. Safety data were collected for all the patients after the administration of 64Cu-DOTA-trastuzumab and during the 1-wk follow-up period. Results: According to our results, the best timing for the assessment of 64Cu-DOTA-trastuzumab uptake by the tumor was 48 h after injection. Radiation exposure during 64Cu-DOTA-trastuzumab PET was equivalent to that during conventional 18F-FDG PET. The radioactivity in the blood was high, but uptake of 64Cu-DOTA-trastuzumab in normal tissues was low. In 2 patients, 64Cu-DOTA-trastuzumab PET showed brain metastases, indicative of blood–brain barrier disruptions. In 3 patients, 64Cu-DOTA-trastuzumab PET imaging also revealed primary breast tumors at the lesion sites initially identified by CT. Conclusion: The findings of this study indicated that 64Cu-DOTA-trastuzumab PET is feasible for the identification of HER2-positive lesions in patients with primary and metastatic breast cancer. The dosimetry and pharmacologic safety results were acceptable at the dose required for adequate PET imaging.